Disclosures:
Disclosure of Financial Relationships
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
| Beth Faiman PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO |
Beth Faiman has disclosed that she received consulting fees from BMS, GSK, J&J, Karyopharm Therapeutics, Pfizer, and Sanofi. |
| Rebecca Lu MSN, FNP-C |
Rebecca Lu has disclosed that she received consulting fees from Kite, Pfizer, Janssen, and Sanofi. |
| Donna D. Catamero ANP-BC, OCN®, CCRC |
Donna Catamero has disclosed that she received speaking honoraria from GSK, J&J, Regeneron, and Sanofi, and consulting fees from Legend Biotech. |
| Tiffany Richards Phd, ANP-BC-AOCNP® |
Tiffany Richards has disclosed that she received consulting fees from BMS, Pfizer, Regeneron, and Sanofi. |
The staff reported the following relevant financial relationships they have with ineligible companies related to the content of this activity:
| Diane Moran RN, MA, EdM |
Diane Moran has no relevant financial relationships to report. |
| Michelle Faber MS |
Michelle Faber has no relevant financial relationships to report. |
| Joyce Divine PhD, MBA |
Joyce Divine has no relevant financial relationships to report. |
All of the relevant financial relationships listed for these individuals have been mitigated.
The PIM planners and others have nothing to disclose.
Off-label use of drugs may be discussed.